In Colo-205 cells, 24-hour LY2835219 exposure inhibited Rb Ser780 phosphorylation and increased the G1 population, with IC50 120 ± 36 nmol/L (n = 6) and G1 EC50 72 ± 31 nmol/L (n = 7), respectively (geometric means ± SD). These are cellular assay endpoints for the methanesulfonate salt. [1]
Cell-cycle effects depend on model and concentration. A later study observed G2 accumulation with abemaciclib at higher concentrations in MCF7 cells and in pRb-deficient PDX12-58 cells; palbociclib and ribociclib did not alter the cell-cycle distribution in the pRb-deficient model. The cellular response therefore extends beyond a universal Rb-dependent G1 arrest. [2]
CDK4/6 biochemical inhibition and selectivity limits
Biochemical assay · Human kinase/cyclin complexes; CDK4/cyclin D1 and CDK6/cyclin D1 use a C-terminal Rb fragment substrate [1]
LY2835219 inhibited CDK4/6 in a radiometric assay and showed ATP-competitive kinetics. CDK9 inhibition in the same profile limits any claim of absolute CDK4/6 specificity. IC50 and Ki are assay endpoints, not treatment doses.
Literature-Reported Treatment Conditions
- Treatment concentration
- 10-point, 1:3 serial dilution; reported starting compound concentration 20 μM
- Exposure duration
- 90 min for CDK4/6 inhibition assays (ESM1 methods)
- Method
- Radiometric-filter binding; four-parameter IC50 fit; competitive Michaelis–Menten kinetic analysis
- Vehicle
- Compound dilution buffer 20% DMSO; DMSO-only and EDTA background controls described. This is not asserted as the final reaction DMSO fraction.
- Reported limits
- No cross-paper comparison of assay ATP conditions is made.
Methods and source locations
Compound reported in the paper: abemaciclib (LY2835219); Compound label in the paper: LY2835219
Reported compound-level evidence; tested material and formulation apply only to this paper. No salt conversion or SKU/lot equivalence is inferred.
Table 1 biochemical rows and footnotes a–b; Enzymatic profiling; Results, Identification of LY2835219
CDK4/cyclin D1 inhibition: Radiometric Rb-fragment assay for CDK4/6; ATP-varied competitive kinetic fitting for Ki. For n > 1, mean of independent determinations ± SD. — Table 1 biochemical profiling, footnotes a–b; Materials and methods, Enzymatic profiling
CDK6/cyclin D1 inhibition: Radiometric Rb-fragment assay for CDK4/6; ATP-varied competitive kinetic fitting for Ki. For n > 1, mean of independent determinations ± SD. — Table 1 biochemical profiling, footnotes a–b; Materials and methods, Enzymatic profiling
CDK4/cyclin D1 inhibition: Radiometric Rb-fragment assay for CDK4/6; ATP-varied competitive kinetic fitting for Ki. For n > 1, mean of independent determinations ± SD. — Table 1 biochemical profiling, footnotes a–b; Materials and methods, Enzymatic profiling
CDK6/cyclin D1 inhibition: Radiometric Rb-fragment assay for CDK4/6; ATP-varied competitive kinetic fitting for Ki. For n > 1, mean of independent determinations ± SD. — Table 1 biochemical profiling, footnotes a–b; Materials and methods, Enzymatic profiling
CDK9/cyclin T1 inhibition: Biochemical kinase profiling, Table 1. CDK9-specific assay protocol was not recovered from the inspected main text; it is not assigned the CDK4/6 Rb-fragment method. — Table 1 biochemical profiling, footnotes a–b; Materials and methods, Enzymatic profiling
Rb phosphorylation and G1 accumulation in Colo-205 cells
Cell-based study · Colo-205 human colorectal cancer cells [1]
A 24-hour multiplexed assay linked reduced Rb Ser780 phosphorylation to increased 2N DNA content and reduced cell-number expansion. Table 1 reports geometric-mean cellular potency estimates ± SD, with different n for the two endpoints.
Literature-Reported Treatment Conditions
- Treatment concentration
- 10-point 1:3 series across 20 μM to 0.001 μM (ESM1 assay method)
- Exposure duration
- 24 h
- Method
- Acumen Explorer multiplexed phospho-Rb immunofluorescence and propidium-iodide DNA-content analysis; four-parameter fits
- Vehicle
- 0.25% final DMSO (ESM1)
- Reported limits
- The tested concentration series is a method range; it is not an IC50. No apoptosis measurement is inferred from reduced cell number.
Methods and source locations
Compound reported in the paper: abemaciclib (LY2835219); Compound label in the paper: LY2835219
Reported compound-level evidence; tested material and formulation apply only to this paper. No salt conversion or SKU/lot equivalence is inferred.
Figure 2a; Table 1 cellular rows and footnote d; Cell assays; ESM1, Cellular assay for inhibition of Phosphorylation of Retinoblastoma Protein and DNA Content Assay
Rb Ser780 phosphorylation inhibition: Multiplexed cellular imaging — Table 1 cellular profiling, footnote d; Figure 2a
Accumulation of cells with 2N DNA content (G1): Multiplexed cellular imaging — Table 1 cellular profiling, footnote d; Figure 2a
Concentration-dependent G1 and G2 cell-cycle responses
Cell-based study · MCF7 breast cancer cells at 24 and 48 h; pRb-deficient PDX12-58 (caption: PDX-1258) cells at 48 h [2]
In Figure 5, abemaciclib caused G1 arrest with reduced phospho-pRb in MCF7 cells and G2 accumulation at higher concentrations. In pRb-deficient PDX12-58 cells it caused G2 accumulation, whereas palbociclib and ribociclib did not alter the cell-cycle distribution. These observations constrain a universal, exclusively Rb-dependent G1-arrest mechanism; this experiment alone does not establish the responsible secondary kinase.
Literature-Reported Treatment Conditions
- Treatment concentration
- Figure 5: 0, 0.1, 0.3, 1.0 and 3.2 μM; matched inhibitor comparison
- Exposure duration
- MCF7: 24 or 48 h; PDX12-58: 48 h
- Method
- Hoechst nuclear DNA-content imaging and phospho-pRb Ser807/811 immunofluorescence; representative of three replicates
- Vehicle
- Zero-drug controls shown; DMSO controls described in shared dose-response methods
- Reported limits
- Final DMSO fraction not specified in the inspected Figure 5 methods. No exact cell-cycle percentages read from histograms; 0.3 μM is a response-context threshold in Results, not an IC50.
Methods and source locations
Compound reported in the paper: abemaciclib (LY2835219); Compound label in the paper: Abemaciclib
Reported compound-level evidence; tested material and formulation apply only to this paper. No salt conversion or SKU/lot equivalence is inferred.
Figure 5 image/caption; Results, Abemaciclib blocks cells in the G2 phase of the cell cycle; STAR Methods, Phospho-pRb immunofluorescence and cell cycle analysis; Key Resources Table
Cell-cycle distribution and phospho-pRb staining: Hoechst DNA content and phospho-pRb Ser807/811 imaging — Figure 5 and caption; Results, Abemaciclib blocks cells in the G2 phase of the cell cycle